Balovaptan
![]() | |
Clinical data | |
---|---|
Other names | RG7314 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H24ClN5O |
Molar mass | 409.92 g·mol−1 |
3D model (JSmol) | |
Balovaptan (INN; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2019, it is in a phase III clinical trial for adults and a phase II clinical trial for children for this indication.[2] On 29 January 2018, Roche announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for balovaptan in individuals with autism spectrum disorder (ASD).[3] The FDA granted this based on the results of the adult phase II clinical trial called VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study.[4] The currently-recruiting (Until March 2020) phase III adult study is called V1aduct and the currently-closed (August 2019) phase II child study is called Av1ation.[citation needed]
See also[]
- ABT-436
- Nelivaptan
- SRX-246
- TS-121
References[]
- ^ "Roche - Pipeline". 2014. Retrieved 1 August 2014.
- ^ Clinical trial number NCT01793441 for "Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders" at ClinicalTrials.gov
- ^ "FDA grants Breakthrough Therapy Designation for Roche's balovaptan in autism spectrum disorder" (Press release). 29 January 2018. Retrieved 6 February 2018.
- ^ Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, et al. (May 2019). "A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder". Science Translational Medicine. 11 (491). doi:10.1126/scitranslmed.aat7838. PMID 31043521.
External links[]
- "Balovaptan". Drug Information Portal. U.S. National Library of Medicine.
- Breakthrough therapy
- Chloroarenes
- Experimental drugs
- Pyridines
- Triazoles
- Vasopressin receptor antagonists
- Nervous system drug stubs